Alcon stock
Price history
+1.79% over the period1 year: from CHF 61.40 (November 17, 2025) to CHF 62.50 (November 16, 2026), +1.79%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | CHF 62.50 |
| October 30, 2026 | CHF 59.10 |
| September 30, 2026 | CHF 53.98 |
| August 31, 2026 | CHF 58.56 |
| July 31, 2026 | CHF 55.38 |
| June 30, 2026 | CHF 54.60 |
| May 29, 2026 | CHF 52.10 |
| April 30, 2026 | CHF 58.22 |
| March 31, 2026 | CHF 59.26 |
| February 27, 2026 | CHF 66.86 |
| January 30, 2026 | CHF 62.42 |
| December 30, 2025 | CHF 63.28 |
| November 28, 2025 | CHF 63.86 |
| November 17, 2025 | CHF 61.40 |
At a glance
The company
Develops and sells eye care products for surgery and vision care, including intraocular lenses, contact lenses and ocular health products
Latest results
Quarter to September 30, 2026 · EPS $0.91 (estimate $0.88)
TickerLandia's take on Alcon
- Pricier than similar companies: trailing 12-month P/E 56 vs 42 (+34%) in a group of 10.
- Strong point: Financial strength (66/100 in its group). Weak point: Dividend (23/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.55% from the 52-week high
Analysts · 27 analysts
Average targetCHF 73.98+18.37% vs. price
Buy 20 · Hold 6 · Sell 1 · Buy
TickerLandia Fingerprint: Alcon
Compared with similar companies: low dividend, high financial strength, and low profitability.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow37
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 56.3 78 Forward P/E 17.0 28 EV/EBITDA 13.8 31 Price/book 1.65 10 Price/sales 2.68 37 Profitabilitylow36
How much it earns on revenue and capital.
Metric Value Position in group Net margin 6.1% 40 ROE 3.0% 13 Gross margin 57.9% 60 Operating margin 12.9% 40 ROA 2.8% 25 Earnings stabilityaverage53
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.2% 43 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage44
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +12.50% 38 Revenue growth (year over year) +4.70% 40 Average revenue growth (3 years) +6.06% 54 Financial strengthhigh66
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 6.25 42 Debt/equitycounts in reverse: lower means more financial strength 0.25 68 Current ratio 2.50 75 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.40 80 Dividendlow23
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.5% 20 Consecutive dividend years 6 years 19 Payout ratio 25.7% 31 Market momentumaverage52
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −1.15% 47 Relative strength (6 months) +8.18% 72 1-year return −2.42% 29 Distance from 200-day average +7.04% 60 Riskaverage53
How much the price swings.
Metric Value Position in group Beta (1 year) 0.79 53 Maximum drawdown (12 months) 27.3% 62 Volatility (60 days) 25.8% 45
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Alcon is pricier than similar companies
Alcon's P/E (trailing 12 months): 56.3, +34% against the median of a group of 10 similar companies (41.9).
Compared with 10 similar companies
| Metric | Alcon | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 56.3 | High | |
| Forward P/E | 17.0 | Low | |
| Operating margin | 12.9% | Low | |
| ROE | 3.0% | Low | |
| Debt/equity | 0.25 | Low |
Grey band: the middle half of the group; tick: the median; dot: Alcon. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$2.74B
Latest quarter · Q3 2026
Net income
$260M
Latest quarter · Q3 2026
Quarterly net margin
9.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- CHF 29.48B
- P/E
- 56.3
- EPS
- CHF 1.09
- Volume
- 1.15M
- Daily trading
- €73.85M
- Dividend yield
- 0.45%
- Last ex-dividend on May 5, 2026
How Alcon is changing
All resultsRevenue grew 8.8% a year on average over the last 5 years
Operating margin rose from 7.7% to 13.1%
Profits turn into cash: free cash flow equal to 137% of net income
Returns
Alcon returns with dividends
CHF 1,000 invested in Alcon 5 years ago, on November 16, 2021, would be worth CHF 826 today with dividends reinvested: −17.43% in total, −3.76% per year. On price alone it would be CHF 812 (−18.83%).
| Period | Alcon | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +14.18% | +8.46% | CHF 1,142 |
| 6 months | +23.96% | +14.27% | CHF 1,240 |
| Year to date | −1.23% | +13.86% | CHF 988 |
| 1 year | +2.28% | +19.91% | CHF 1,023 |
| 3 years | +1.53% | +41.93% | CHF 1,015 |
| 5 years | −17.43% | +20.30% | CHF 826 |
Over the last 6 months it has done better than 37% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Alcon: technical analysis
Alcon shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 26.2% below its all-time closing high (CHF 84.68, September 12, 2024).
- Trend
- No clear trend
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +9.02%
Support and resistance
Price areas where Alcon has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceCHF 65.71+5.13%3 touches, last on January 22, 2026
- ResistanceCHF 64.17+2.68%3 touches, last on November 5, 2026
- Last priceCHF 62.50
- SupportCHF 61.92−0.92%4 touches, last on August 11, 2026
- SupportCHF 59.62−4.61%2 touches, last on September 2, 2026
- SupportCHF 56.12−10.21%3 touches, last on July 3, 2026
Volatility and risk
Over the last year it has moved less than the SMI.
- Beta (1 year) vs SMI
- 0.78
- Volatility (60 sessions, annualised)
- 26.1%
- Largest fall in the last year
- −27.30%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Alcon: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Alcon has been February: +2.38% on average, positive in 4 years out of 7. The weakest has been September: −3.39% on average, positive in 3 years out of 8. November, the current month, has been positive in 4 years out of 7 (+2.04% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.33% | +3.91% | 4 of 7 |
| February | +2.38% | +0.34% | 4 of 7 |
| March | −2.59% | −0.22% | 3 of 7 |
| April | −1.22% | −1.75% | 3 of 7 |
| May | +1.80% | +0.68% | 4 of 8 |
| June | −0.43% | +1.69% | 4 of 8 |
| July | +2.31% | +1.66% | 6 of 8 |
| August | −1.09% | −0.73% | 3 of 8 |
| September | −3.39% | −3.76% | 3 of 8 |
| October | +0.02% | −0.14% | 4 of 8 |
| November | +2.04% | +1.70% | 4 of 7 |
| December | +1.02% | −0.74% | 2 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Alcon and its competitors
With 25,000 employees, Alcon develops, makes and sells eye care products for surgery and daily vision. Its Surgical activities cover equipment, diagnostics and intraocular lenses, along with consumables for cataract and vitreoretinal procedures and refractive systems such as WaveLight. Its Vision Care activities include contact lenses and ocular health products for conditions such as dry eye, allergies and glaucoma, and the company is also developing encapsulated cell therapies for chronic eye diseases.
- Headquarters
- Geneva, Switzerland
- Employees
- 25,000
- Founded
- 1945
- Chief executive
- David Endicott
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AlconALC | $35.16B | 12.9% | 56.3 | +23.96% |
| Sartorius Stedim BiotechDIM | $24B | 19.2% | 67.0 | +44.71% |
| Straumann HoldingSTMN | $20.43B | 24.7% | 46.5 | +30.89% |
| SartoriusSRT | $19.89B | 17.8% | 79.3 | +38.35% |
| ColoplastCOLO.B | $16.93B | 25.7% | 37.2 | +27.32% |
| EssilorLuxotticaEL | $92.38B | 12.8% | 34.1 | +6.67% |
Same industry or related industries, similar size. Compare Alcon with its competitors · Full profile
